Purpose: Local anesthetics are administered intraarticularly for pain control in orthopedic clinics and surgeries. Although previous studies have shown that local anesthetics can be toxic to chondrocytes, the underlying mechanism remains unclear. The present study was undertaken to investigate the cellular mechanisms associated with lidocaine-induced toxicity to articular chondrocytes. Methods: Isolated rabbit articular chondrocytes were exposed for 30 minutes to lidocaine at concentrations of 1, 3, 10 and 30 mM (360 mosmol$L-1, pH 6.8, 7.4 and 8.7) at 36 C. To evaluate the lidocaineinduced blebbing, morphological changes of chondrocytes were monitored using time-lapse microscopy and then the percentage of blebbing cells was evaluated every minute. The levels of guanosine triphosphate (GTP)-bound RhoA and caspase-3 were determined using a RhoA G-LISA assay and a Caspase-Glo 3/7 assay. The viability of chondrocytes treated with 30 mM lidocaine for an hour was determined using a LIVE/DEAD ® assay kit. To evaluate the percentage of living cells, the number of living cells (green) and dead cells (red) of each image were counted by an ImageJ software. Results: Treatment of chondrocytes with lidocaine caused spherical protrusions on the cell surface (so called 'membrane blebbing') in a time-and concentration-dependent manner. After 30-min exposure, lidocaine (pH 7.4) at the concentrations of 1, 3, 10 and 30 mM induced membrane blebbing in 9.6±1.1%, 35.5±11.6%, 84.1±2.2% and 100±0% of chondrocytes, respectively, compared with the controls (1.2±2.1%) (mean±s.d., n¼3). These effects of lidocaine could be fitted by the Hill equation giving an EC50 of 4.13 mM, which is lower than clinical use concentrations. When lidocaine was applied under alkaline (pH8.7) or acidic (pH 6.8) condition, the EC50s were shifted to 1.37 or 11.72 mM, respectively, as is expected for the pH-dependent change in the concentration of non-ionized lidocaine. ROCK (Rho-kinase) inhibitors Y-27632 (10 mM) and fasudil (100 mM) completely inhibited the lidocaineinduced membrane blebbing, suggesting that ROCK activation is required for the blebbing. Although the apoptotic blebbing is typically caused by the caspase-3-induced cleavage of ROCK-I, the caspase-3 level was unchanged by 20-min treatment of chondrocytes with 10 mM lidocaine. Furthermore, although it was reported that apoptotic blebbing was abrogated by z-VAD-fmk, a caspase inhibitor, this drug did not prevent the lidocaine-induced blebbing. These results suggest that lidocaine-induced membrane blebbing is independent of caspase-3 activity. The GTP-bound RhoA level was significantly increased (3.01±0.76 folds, P < 0.0001) by 20-min treatment of chondrocytes with 10 mM lidocaine. However, Rho inhibitor-1 rather enhanced the membrane blebbing, suggesting that the lidocaine-induced membrane blebbing might be at least partially mediated through the pathway other than canonical Rho/ROCK signaling. Chondrocyte viability was significantly decreased to 17.6±5.7% after 1-h exposure to 30 mM lidocaine, compared with the control viability of 94.8±2.4% (P < 0.0001). Pretreatment with Y-27632 or fasudil for 1-hour attenuated the lidocaine induced-cytotoxicity (49.4±12.5% and 47.2±9.1% viability respectively, P < 0.0001), demonstrating that the lidocaine-induced hyperactivation of ROCK leaded to chondrotoxicity. Conclusions: These findings show that lidocaine induces a cytotoxic effect on chondrocytes through the mechanism involving membrane bleb formation and ROCK activation and that caution should be taken when administering lidocaine intraarticularly. Purpose: Exposure of joint cartilage to blood can occur after joint trauma, during or after major joint surgery, or due to hemophilia. This ultimately leads to joint damage, having both the inflammatory characteristics of rheumatoid arthritis and the degenerative characteristics of osteoarthritis. We previously reported that blocking interleukin(IL)-1b with a recombinant monoclonal antibody (IL-1bmAb) protects cartilage from the damaging effects of blood exposure in a dose-dependent way (Abstract 155; 2014 World Congress on Osteoarthritis). To further unravel the role of IL-1b in blood-induced cartilage damage, we investigated whether blocking IL-1 with a receptor antagonist (IL-1RA) is also able to prevent blood-induced cartilage damage in vitro, and whether blocking IL-1b with either IL-1RA or IL-1bmAb after onset of a bleed is still beneficial. Methods: Healthy human cartilage explants were cultured for 4 days in presence/absence of 50% whole blood. IL-1RA was added in a broad concentration range (10-1000 ng/mL) during blood exposure (n¼7). Furthermore, IL-1bmAb (100 ng/mL) or IL-1RA (1000 ng/mL) was administered directly or after a delay of several hours up to 2 days (n¼7). Proteoglycan turnover was determined after a recovery period of 12 days. Moreover, in 4-day whole blood cultures (n¼6) the effects of IL-1bmAb (100 ng/mL) and IL-1RA (1000 ng/mL) on the levels of IL-1b, IL-6, and TNF-a were determined. Results: Exposure of cartilage to blood severely impacted proteoglycan turnover (PG synthesis -76%; p¼0.018 see figure A ; PG release þ125%; p¼0.018; PG content -18%; p¼0.028; all compared to control). Addition of IL-1RA resulted in a clear dose-dependent improvement in proteoglycan turnover (see figure A for proteoglycan synthesis). For PG release and PG content, the highest concentration led to normalisation as compared to control (PG release þ33% of control (p¼0.063); PG content þ2% of control (p¼0.866)). The protective effect of IL-1bmAb or IL-1RA was most pronounced when administered within 8 hours after the bleed (see figure B for proteoglycan synthesis upon IL-1RA addition). Blocking IL-1b reduced IL-6 (21 347 pg/mL in whole blood culture versus 27 pg/mL and 289 pg/mL after addition of IL-1RA and IL-1bmAb (both p¼0.028)) and IL-1b (74 pg/mL in whole blood culture versus undetectable after addition of IL-1RA, p¼0.028) levels in whole blood cultures, but did not affect the levels of TNF-a (35 pg/mL in whole blood culture versus 37 pg/mL after addition of IL-1RA or IL-1bmAb (both p¼0.753)).
Conclusions: This study demonstrates that IL-1b is a critical factor in the development of blood-induced cartilage damage in vitro. Blocking it with either a monoclonal antibody or receptor antagonist protects cartilage from the damaging effects of blood exposure in a dose-and time-dependent way. Early administration after blood-exposure is most beneficial. This key role of IL-1b results at least partly from regulating the production of other pro-inflammatory cytokines, including IL-1b itself and IL-6. As therapeutic agents opposing the activity of IL-1b are readily available, further research is warranted to investigate its in vivo capacity in prevention and treatment of joint damage upon joint bleeding.
THE ROLE OF SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR 1 IN OSTEOARTHRITIS
R. White, M.C. Blair, F.R. Saunders, R.M. Aspden. Univ. of Aberdeen, Aberdeen, United Kingdom Purpose: In a pilot study, selected gene expression in tissue samples from patients with OA and osteoporosis (OP) were compared. The gene, SLC9A3R1 which encodes for a member of the sodium/hydrogen regulatory factor protein family (NHERF1) was found to be differentially expressed in osteoblasts. NHERF1 plays a role in tumour suppression, via PTEN, and intracellular pH (pHi) regulation by acting on the sodium/ hydrogen exchanger (NHE). We are investigating whether a decrease in NHERF1 causes a change in the pHi of chondrocytes and leads to chondrocyte proliferation. The aim of the project is to test the hypothesis that dysregulated expression of NHERF1 is a key part of the abnormal behaviour of articular chondrocytes. Methods: Full depth cartilage explants or shavings were removed from osteoarthritic femoral heads or knee joints, and from healthy controls (amputees or osteoporotic femoral heads). Explants from 17 patients (4 OA and 4 non-OA femoral heads, 4 OA knees and 5 amputees) were decalcified and fixed in formalin for paraffin embedding and sectioning, whilst shavings were placed in Dulbecco's Modified Eagles Medium (DMEM) and washed prior to enzymatic chondrocyte isolation. Sections were deparaffinised and either stained with Fast-Green-FCF and Safranin 'O', or treated with Target Retrieval Solution and hyaluronidase prior to incubation with glycine, blocking with non-immune serum and overnight incubation with either rabbit anti-human NHE3 (pAb, C-20), mouse anti-human NHERF1 (mAb, IgG2b), or goat anti-human PTEN (pAb, N19) diluted in Dako Antibody Diluent (1:50: PTEN 1:100). Bound NHE3, NHERF1 or PTEN antibodies were detected with goat anti-rabbit (488 nm), goat anti-mouse (555 nm) or donkey anti-goat (488 nm) secondary antibodies (1:100, PTEN 1:200) respectively. Sections were mounted with Prolong Gold anti-fade mounting media containing DAPI and visualized with a Zeiss Imager M2 fluorescent or LSM 700 Zeiss Imager M2 confocal laser scanning microscope (CLSM). Cell counts and co-localisation were analysed using Image J software. Isolated articular chondrocytes (n¼3) were incubated with BCECF-AM (5 mM, 15 mins, 37 oC), washed in DMEM without phenol red, aliquoted ( 14 x 104) and placed in a sterile Ibidi m-Slide I (0.4) Flow Chamber (Thistle Scientific, UK) for 20-30 min (37 oC) to attach. They were washed into the appropriate saline,After saline washing, and BCECF was then alternately excited at 488 nm and 458 nm, and emission collected at >505 nm using a CLSM (Zeiss LSM 710) from individual cells. The background from each wavelength was subtracted and the 488:458 nm ratio (R) converted to pHi using a calibration curve constructed by permeabilizing the chondrocytes to Hþ in high-potassium (Kþ) solutions of different pH containing nigericin (2 mM).
Results: NHE3, NHERF1 and PTEN were expressed in all zones of OA and non-OA articular cartilage. Image J analysis showed that NHERF1 colocalised with both proteins in the cytoplasm and perinuclear region, but little was found near the cell membrane. It was also expressed in the nucleus in 50% of chondrocytes in OA and non-OA samples. The median diameter of the nuclei of OA chondrocytes was also found to be significantly larger (7.47 mm) than in non-OA chondrocytes (6.78 mm, P¼0.001???). The pHi of normal, healthy chondrocytes was 6.9 þ 0.2 (n¼3) but OA chondrocytes appeared to be more acidic. The pHi of these chondrocytes was too low to be recorded successfully and reliably using BCECF (pKa 6.98) which is used for measuring near neutral pH, so this necessitated exploring the use of another fluorescein derivative, DCFDA (pKa 4.8) for pH measurements from pH 4-5 Conclusions: This is the first study to identify NHE3, NHERF1 and PTEN expression and co-localisation in human articular cartilage, and to measure pHi in single isolated chondrocytes using confocal microscopy and the fluorescent dyes, BCECF-AM and DCFDA. NHERF1 was expected at the cell membrane but, surprisingly, location was predominantly cytoplasmic. Detection of NHERF1 expression and function in articular cartilage may open new approaches for OA therapy in the future. y Lancaster Univ., Lancaster, United Kingdom; z Duke Univ., Durham, NC, USA;
ANALYSIS OF CARTILAGE BIOMARKERS OF AGING AND TURNOVER IN
x Univ. of Liverpool, Liverpool, United Kingdom Purpose: Alkaptonuria (AKU) is a rare autosomal recessive disease that results from a single enzyme deficiency in the tyrosine metabolic pathway. As a result, homogentisic acid (HGA), a metabolite of tyrosine, cannot be broken down; despite some urinary excretion, this results in systemic increases in HGA concentrations. Over time, HGA undergoes polymerization, termed ochronosis, and deposits as a polymer in collagenous tissues. Typically this occurs in joint cartilages and leads to an early onset, rapidly progressing osteoarthropathy. The literature suggests that all AKU patients will develop osteoarthropathy, and many will have multiple joint involvement. Little is currently known about tissue turnover in cartilage affected by ochronosis and the impact of this turnover on disease initiation and progression. We investigated the turnover of AKU cartilage using biomarkers of turnover and aging and compared these to both OA and non-arthritic control cartilage tissues. We hypothesized that novel age-related biomarkers would provide insights into cartilage turnover in the context of AKU versus OA cartilage. Methods: Samples of hip and knee cartilage were obtained with informed patient consent at the time of joint arthroplasty surgery for arthropathy due to alkaptonuria (n¼6) and osteoarthritis (OA, n¼12). Non-arthritic cartilages (n¼6) were obtained as waste tissues after trauma surgery. We measured cartilage concentrations (normalized to dry weight) of several biomarkers including glycosaminoglycan (GAG), total cartilage oligomeric matrix protein (COMP) and two age-related biomarkers, deamidated COMP (dCOMP) and aspartate ratio (Asp ratio representing the proportion of racemized to total aspartate). Using the nonparametric Mann-Whitney U test for unpaired data, biomarker results from alkaptonuria samples were compared to results from OA and non-OA normal samples. Results: The cartilage samples used for this study represent almost 10% of the known alkaptonuric population in the UK (knees n¼2, mean age 59.5 years and hips n¼4, mean age 61 years). Compared to both Non-OA (knee n¼1, mean age 36 years and hip n¼5, mean age 63.4 years) and OA (knee n¼5, mean age 68.6 years and hip n¼7, mean age 80.5 years) samples, the mean amount of extractable protein from AKU cartilage samples was significantly greater (p¼0.002 and 0.035 respectively). However, normalized to total protein, the mean amount of extractable GAG (p<0.002) and total COMP (p<0.002) were significantly lower in AKU cartilage samples compared to both Non-OA and OA samples. The age-related biomarkers, mean extractable dCOMP (expressed as a proportion of total COMP) and mean Asp ratio, were both significantly higher in AKU cartilage samples compared to OA samples (p¼0.04 and p¼0.004, respectively) but not relative to Non-OA cartilage. Conclusions: To our knowledge these novel data represent the first examination of cartilage matrix components from patients with AKU, compared with OA and non-arthritic normal controls. These data demonstrate a significantly reduced amount of extractable GAG and COMP suggestive of an impaired anabolic response. Further support for lack of appropriate repair response in AKU cartilages was provided by the results for the age-related biomarkers; both age-related biomarkers were enriched in AKU relative to OA cartilages suggesting lack of an anabolic response in degenerating cartilage in AKU. These data suggest that individuals with AKU may benefit from growth factor and other anabolic treatments as there appears to be a lack of an anabolic response to the cartilage degeneration associated with the pathological ochronotic pigmentation process. Purpose: The synovium, bone, and cartilage are each involved in pathologic processes that lead to progressive joint degeneration. In concert with cartilage degeneration, the subchondral plate in knee joints affected by OA has been shown to have increased bone volume fraction and trabecular thickness, but reduced tissue mineral density, consistent with OA being associated with abnormalities in bone turnover. We have identified, using Affymetrix microarray screening and confirmatory QPCR, that periostin -an osteoblast stimulatory factor encoded by the gene Postn -is significantly overexpressed by chondrocytes and subchondral bone in OA. We have also found that periostin mRNA expression in cartilage is increased in both rat meniscectomy (MM) and anterior crucial ligament (ACL) surgical models of OA. This study investigates its expression in rodent models of OA and regulation of chondrocyte metabolism.
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